EverImmune Reports the First Patient Dosing of Oncobax AK in the P-I Clinical Trial for Lung and Kidney Cancer
Shots:
- The first patient has been treated in the P-I trial (EV 2101) evaluating Oncobax AK in patients with lung and kidney cancer. Additionally, ~60 patient plans to be enrolled where 19 with NSCLC and 41 with RCC at four sites in France and Belgium
- The purpose of the trial is to evaluate the toxicity and efficacy of Oncobax AK in improving immunotherapy outcomes. The results are expected at the end of H1’23
- Patients in the trial who are deficient in Akkermansia and are resistant to immunotherapy are selected using a screening test. The P-IIa trial is expected to be initiated during 2023
Ref: Pharmiweb | Image: EverImmune
Related News:- Lydus Medical’s Vesseal Device Receives the US FDA’s Clearance for Small Arteries
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
